- Home
- EDTK vs CTXR Comparison
EDTK vs CTXR Comparison
Compare EDTK & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | CTXR |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 18.7M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EDTK | CTXR |
|---|---|---|
| Price | $0.98 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 13.3K | ★ 890.2K |
| Earning Date | 01-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.47 |
| 52 Week High | $1.18 | $2.19 |
Technical Indicators
Market Signals| Indicator | EDTK | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 48.46 |
| Support Level | $0.96 | $0.51 |
| Resistance Level | $1.06 | $0.61 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.52 | 19.72 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.